
Imcivree Coupons & Savings Card – Discount Prices from $3617.11
My prescription
Edit
1ML of 10MG/ML, Imcivree (1 Vial)
Select pharmacy

Rite Aid
$3617.11
COUPON PRICE
Albertsons
$3679.29
COUPON PRICE
Walgreens
$3736.09
COUPON PRICE
Walmart
$3764.67
COUPON PRICEImcivree savings card
Show this card to your pharmacist
Rite Aid
$3617.11
BIN
ID
PCN
GRP
019876
LH74FFEC7F
CHIPPO
LHX
Powered by
Related melanocortin receptor agonists prescriptions
More prescriptions for weight loss
Related melanocortin receptor agonists prescriptions
More prescriptions for weight loss
Imcivree dosage forms
Dosage | Quantity | Price from | Per unit |
---|---|---|---|
1ML of 10MG/ML | 1 Vial | $3617.11 | $3617.11 |
Imcivree Warnings
The medication Imcivree (setmelanotide) has several important safety warnings that users should be aware of. It is crucial to understand these risks and discuss any concerns with your healthcare provider. Below are the key warnings associated with this medication:
Sexual Function Issues: Some individuals may experience sexual problems, including unexpected penile erections in males and unwanted sexual arousal in females. If these occur, consult your prescriber. Seek immediate medical assistance if an erection lasts longer than four hours, as this could lead to permanent damage.
Mental Health Concerns: Imcivree (setmelanotide) may cause or exacerbate depression and suicidal thoughts or behaviors. Notify your prescriber promptly if you or those around you observe any mood or behavior changes or if you have thoughts of self-harm. Patients with a history of depression or suicidal thoughts are at a higher risk and may need to discontinue the medication.
Allergic Reactions: Although uncommon, allergic reactions can occur, usually within minutes to hours after an injection. Symptoms like difficulty breathing, throat tightness, or swelling of the face or tongue require immediate medical attention.
Skin Darkening (Hyperpigmentation): This medication may cause darkening of the skin or moles, which typically resolves after discontinuation. Regular full-body skin examinations by your healthcare provider are recommended before and during treatment to monitor for new skin spots.
Serious Risks to Newborns and Low Birth Weight Infants: The preservative benzyl alcohol in Imcivree (setmelanotide) can cause severe, life-threatening reactions in newborns, such as "gasping syndrome," which impacts brain function, blood acidity, and breathing. Therefore, this medication should not be used in newborns or young infants.
Always consult with your healthcare provider for personalized medical advice and before making any changes to your medication regimen.
Imcivree Side Effects
When taking this medication, some common side effects may include mild reactions at the injection site, such as redness, itching, swelling, or pain. Additionally, you might experience skin discoloration, nausea, headache, diarrhea, stomach pain, back pain, tiredness, vomiting, and unplanned penile erections. Though these effects are generally mild, consult your healthcare provider if they persist or worsen.
Other side effects that have been noted include joint pain, weakness, dizziness, dry mouth, dry skin, trouble sleeping, vertigo, hair loss, chills, constipation, flu-like symptoms, muscle spasms, pain in your arms or legs, and rash. It's advisable to inform your healthcare provider if you encounter any of these symptoms.
Certain side effects are rare but serious and warrant immediate medical attention. These include severe depression, suicidal thoughts, and prolonged erections lasting more than four hours. Additionally, a severe allergic reaction may occur, characterized by trouble breathing, swallowing difficulties, a rapid heartbeat, or swelling of the face, lips, tongue, or throat. If you experience any of these severe symptoms, seek urgent medical care. Always stay informed about potential side effects and communicate any concerns with your healthcare provider.
Is imcivree the same as wegovy?
Imcivree and Wegovy are not the same. Imcivree (setmelanotide) is used for chronic weight management in patients with certain rare genetic conditions, while Wegovy (semaglutide) is used for chronic weight management in adults with obesity or overweight with at least one weight-related condition. They have different active ingredients and mechanisms of action.
What is the use of Imcivree?
Imcivree is used to treat chronic weight management in patients with obesity due to certain genetic conditions, specifically those related to POMC, PCSK1, or LEPR deficiencies. It works by targeting the melanocortin-4 receptor pathway, which is involved in regulating hunger and energy expenditure.
Is Imcivree approved by the FDA?
Yes, Imcivree (setmelanotide) is approved by the FDA. It is indicated for chronic weight management in patients with certain rare genetic conditions that lead to obesity.
What are the criteria for Imcivree?
Imcivree (setmelanotide) is indicated for chronic weight management in patients with obesity due to certain genetic conditions. The criteria for its use include:1. Genetic Confirmation: The patient must have a confirmed diagnosis of obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome, as determined by genetic testing.2. Age Requirement: It is approved for use in patients aged 6 years and older.3. Weight Management: It is intended for chronic weight management and should be part of a comprehensive weight management program that includes dietary and lifestyle modifications.4. Monitoring: Regular monitoring of weight and other health parameters is necessary to assess the effectiveness and safety of the treatment.These criteria ensure that Imcivree is used appropriately in patients who are most likely to benefit from its effects.
How much weight can you lose on Imcivree?
The amount of weight loss on Imcivree (setmelanotide) can vary depending on the individual and the specific genetic condition being treated. In clinical trials, patients with certain genetic obesity disorders experienced significant weight loss. For example, individuals with POMC or LEPR deficiency had an average weight loss of around 10% to 25% of their initial body weight. However, results can differ based on individual factors and adherence to the treatment plan. It is important for patients to discuss their specific situation and potential outcomes with their healthcare provider.